Elevated Uric Acid and Metabolic Dysfunction—Associated Steatotic Liver Disease Progression: Where There's Smoke, is There Fire?
Seminars in Liver Disease · 2026-06 · 46 (02) · 116-134
DOI: 10.1055/a-2926-5268 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 21.08.2026. Verfasst von Eric E Kelley und 2 weiteren Autor:innen. Beteiligte Einrichtung: West Virginia University School of Medicine, Department of Physiology, Pharmacology and Toxicology, West Virginia, United States, Morgantown. Hauptthemen laut MEDLINE: Uric Acid, Hyperuricemia, Fatty Liver, Liver. Die Arbeit nennt 262 Literaturangaben. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Hyperuricemia and metabolic dysfunction–associated steatotic liver disease share overlapping risk factors, yet the mechanistic contribution of uric acid remains unclear. Generation of uric acid occurs exclusively by xanthine oxidoreductase, a process intrinsically linked to electron transfer and oxidant generation, a relationship that can be viewed through electron accounting. This biochemical coupling makes it difficult to determine whether elevated uric acid drives pathology or reflects broader changes in increased redox/oxidative stress. This review highlights mechanisms of uric acid production, its dual antioxidant and pro-oxidant effects, and regulation of urate transporters. We then discuss how western dietary patterns, adiposity, and insulin resistance reshape uric acid homeostasis and intersect with pathways that promote steatosis, inflammation, and fibrogenesis. In conclusion, by framing uric acid within a liver-centered redox perspective, we consider whether elevated uric acid functions as a biomarker of metabolic stress, a contributor to disease progression, and a potential therapeutic target in metabolic dysfunction–associated steatotic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- West Virginia University School of Medicine, Department of Physiology, Pharmacology and Toxicology, West Virginia, United States, Morgantown.
- University of Maryland School of Medicine, Departments of Physiology and Medicine, Maryland, United States, Baltimore.
- University of Pittsburgh, Organ Pathobiology and Therapeutics Institute, Department of Pharmacology and Chemical Biology, Pennsylvania, United States, Pittsburgh.
ORCID-Profile: Owen M Woodward, Nicholas K H Khoo
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kelley, E. E., Woodward, O. M., & Khoo, N. K. H. (2026). Elevated Uric Acid and Metabolic Dysfunction—Associated Steatotic Liver Disease Progression: Where There's Smoke, is There Fire?. Seminars in Liver Disease, 46(02), 116-134. https://doi.org/10.1055/a-2926-5268
Vancouver
Kelley EE, Woodward OM, Khoo NKH. Elevated Uric Acid and Metabolic Dysfunction—Associated Steatotic Liver Disease Progression: Where There's Smoke, is There Fire?. Seminars in Liver Disease. 2026;46(02):116-134. doi:10.1055/a-2926-5268
BibTeX
@article{Kelley2026,
author = {Kelley, Eric E and Woodward, Owen M and Khoo, Nicholas K H},
title = {Elevated Uric Acid and Metabolic Dysfunction—Associated Steatotic Liver Disease Progression: Where There's Smoke, is There Fire?},
journal = {Seminars in Liver Disease},
year = {2026},
volume = {46},
number = {02},
pages = {116--134},
doi = {10.1055/a-2926-5268}
}
EUVIMED